David I Quinn, MD

Clinical Professor of Medicine

Websites

Is this your profile? Click to edit

Overview

David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

Dr. Quinn’s current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

Awards

Castle Connolly Medical: America’s Top Doctors, 2010
USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002
Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001
National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000-2003
St. Vincent’s Clinic Foundation: The David Wilson Travelling Fellowship, 2000
Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000
National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996-1999
University of New South Wales: Gordon Lowe Memorial Prize, 1987
University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987

Publications

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providersUrol Oncol. 2017 07; 35(7):459. e15-459. e24. . View in PubMed
Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysisUrol Oncol. 2022 01; 40(1):12. e13-12. e22. . View in PubMed
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide Eur Urol Oncol. 2024 Mar 23. . View in PubMed
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel Prostate Cancer Prostatic Dis. 2024 Feb 29. . View in PubMed
The Complementary Roles of Open and Endovascular Repair of Extent I -III Thoracoabdominal Aortic Aneurysms in a United Kingdom Aortic Centre Eur J Vasc Endovasc Surg. 2024 Feb 23. . View in PubMed
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel Eur Urol. 2024 Feb; 85(2):171-176. . View in PubMed
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial Eur Urol. 2024 01; 85(1):8-12. . View in PubMed
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study BMC Cancer. 2023 Nov 03; 23(1):1056. . View in PubMed
EphrinB2: Expression of a novel potential target in renal cell carcinoma Indian J Urol. 2023 Jul-Sep; 39(3):223-227. . View in PubMed
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314 Eur Urol Oncol. 2023 10; 6(5):516-524. . View in PubMed
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression J Clin Oncol. 2023 01 20; 41(3):629-639. . View in PubMed
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma J Clin Oncol. 2023 01 20; 41(3):640-650. . View in PubMed
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy Clin Cancer Res. 2023 06 01; 29(11):2052-2065. . View in PubMed
SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer Cancer Res. 2023 11 15; 83(22):3813-3826. . View in PubMed
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers Nat Commun. 2023 02 06; 14(1):630. . View in PubMed
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial JAMA Netw Open. 2023 08 01; 6(8):e2326546. . View in PubMed
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials Clin Cancer Res. 2023 07 05; 29(13):2426-2434. . View in PubMed
Radiogenomic Associations Clear Cell Renal Cell Carcinoma: An Exploratory Study Oncology. 2023; 101(6):375-388. . View in PubMed
Outcomes of temporary mechanical circulatory support in cardiogenic shock due to end-stage heart failure J Intensive Care Soc. 2022 May; 23(2):170-176. . View in PubMed
Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis Int J Mol Sci. 2022 Feb 25; 23(5). . View in PubMed
Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases J Urol. 2022 Feb; 207(2):302-313. . View in PubMed
Thoracic aortic aneurysm repair using the elephant trunk technique and associated complications Clin Radiol. 2022 11; 77(11):803-809. . View in PubMed
Oligometastatic Prostate Cancer: Current Status and Future Challenges J Nucl Med. 2022 11; 63(11):1628-1635. . View in PubMed
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer Curr Oncol Rep. 2022 10; 24(10):1287-1298. . View in PubMed
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma Clin Genitourin Cancer. 2022 10; 20(5):415-422. . View in PubMed
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol. 2022 09; 23(9):1133-1144. . View in PubMed
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial Eur Urol. 2022 05; 81(5):515-522. . View in PubMed
Assessing hypoxic damage to placental trophoblasts by measuring membrane viscosity of extracellular vesicles Placenta. 2022 04; 121:14-22. . View in PubMed
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape Ann Oncol. 2022 03; 33(3):242-243. . View in PubMed
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma Clin Genitourin Cancer. 2022 02; 20(1):35-42. . View in PubMed
Reply by Authors J Urol. 2022 02; 207(2):313. . View in PubMed
Open surgical replacement of the descending thoracic and thoracoabdominal aorta in patients with confirmed Marfan and Loeys-Dietz syndromes: A 20-year single-centre experience Eur J Cardiothorac Surg. 2022 08 03; 62(3). . View in PubMed
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer Nat Commun. 2022 11 04; 13(1):6658. . View in PubMed
Living with a left ventricular assist device: Capturing recipients experiences using group concept mapping software PLoS One. 2022; 17(9):e0273108. . View in PubMed
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials Clin Cancer Res. 2022 05 13; 28(10):2050-2060. . View in PubMed
Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma Eur J Radiol Open. 2022; 9:100440. . View in PubMed
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) J Clin Oncol. 2022 10 01; 40(28):3301-3309. . View in PubMed
Cardiac Power Output Index and Severe Primary Graft Dysfunction After Heart Transplantation J Cardiothorac Vasc Anesth. 2021 Feb; 35(2):398-403. . View in PubMed
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors Invest New Drugs. 2021 12; 39(6):1656-1663. . View in PubMed
Pathophysiology of severe primary graft dysfunction in orthotopic heart transplantation Clin Transplant. 2021 09; 35(9):e14398. . View in PubMed
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 Invest New Drugs. 2021 06; 39(3):812-820. . View in PubMed
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial Lancet Oncol. 2021 06; 22(6):872-882. . View in PubMed
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups ESMO Open. 2021 06; 6(3):100105. . View in PubMed
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide ESMO Open. 2021 04; 6(2):100082. . View in PubMed
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. . View in PubMed
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer Clin Cancer Res. 2021 03 01; 27(5):1391-1398. . View in PubMed
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) Clin Cancer Res. 2021 04 01; 27(7):1967-1973. . View in PubMed
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma N Engl J Med. 2021 08 19; 385(8):683-694. . View in PubMed
Identification of 22 susceptibility loci associated with testicular germ cell tumors Nat Commun. 2021 07 23; 12(1):4487. . View in PubMed
Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways Biol Open. 2021 02 25; 10(2). . View in PubMed
Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer Cancer Biother Radiopharm. 2020 Sep; 35(7):485-489. . View in PubMed
EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy Pathol Res Pract. 2020 Jun; 216(6):152967. . View in PubMed
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. . View in PubMed
Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence Trials. 2020 Feb 11; 21(1):167. . View in PubMed
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma Eur Urol. 2020 12; 78(6):916-924. . View in PubMed
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma Invest New Drugs. 2020 12; 38(6):1807-1814. . View in PubMed
Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent StudiesClin Genitourin Cancer. 2020 10; 18(5):351-360. e3. . View in PubMed
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry Prostate Cancer Prostatic Dis. 2020 09; 23(3):517-526. . View in PubMed
Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters JCO Clin Cancer Inform. 2020 09; 4:839-853. . View in PubMed
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer Prostate Cancer Prostatic Dis. 2020 09; 23(3):486-493. . View in PubMed
Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials Am J Clin Oncol. 2020 08; 43(8):559-566. . View in PubMed
Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature Clin Genitourin Cancer. 2020 08; 18(4):e473-e477. . View in PubMed
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer Ann Oncol. 2020 07; 31(7):930-941. . View in PubMed
Editorial Comment J Urol. 2020 02; 203(2):336-337. . View in PubMed
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma J Clin Oncol. 2020 04 01; 38(10):1041-1049. . View in PubMed
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data Cancer. 2020 06 15; 126(12):2935-2937. . View in PubMed
Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 10, RECIST 1. 1, and PSA response criteria. Theranostics. 2020; 10(7):3254-3262. . View in PubMed
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results Cancer. 2020 06 01; 126(11):2597-2606. . View in PubMed
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer J Clin Oncol. 2020 06 01; 38(16):1797-1806. . View in PubMed
Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 05 15; 146(10):2845-2854. . View in PubMed
Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts Cancers (Basel). 2019 Apr 24; 11(4). . View in PubMed
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048 Kidney Cancer. 2019 Feb 05; 3(1):51-61. . View in PubMed
Accurate blood pressure during patient arm movement: the Welch Allyn Connex Spot Monitor’s SureBP algorithm Blood Press Monit. 2019 Feb; 24(1):42-44. . View in PubMed
Radium-223 mechanism of action: implications for use in treatment combinations Nat Rev Urol. 2019 12; 16(12):745-756. . View in PubMed
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT J Nucl Med. 2019 11; 60(11):1524-1530. . View in PubMed
p53 nuclear accumulation as an early indicator of lethal prostate cancer Br J Cancer. 2019 10; 121(7):578-583. . View in PubMed
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma Invest New Drugs. 2019 08; 37(4):755-762. . View in PubMed
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2019 02; 566(7745):E11-E12. . View in PubMed
Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer Urol Oncol. 2019 01; 37(1):1-11. . View in PubMed
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653) J Clin Oncol. 2019 10 10; 37(29):2682-2688. . View in PubMed
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) J Immunother Cancer. 2019 12 20; 7(1):354. . View in PubMed
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib Clin Cancer Res. 2019 12 15; 25(24):7381-7387. . View in PubMed
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer Cancer. 2019 12 01; 125(23):4172-4180. . View in PubMed
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 11 01; 125(21):3853-3863. . View in PubMed
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up Ann Oncol. 2019 06 01; 30(6):970-976. . View in PubMed
Multiparametric liquid biopsy analysis in metastatic prostate cancer JCI Insight. 2019 03 07; 4(5). . View in PubMed
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223 Cancer Treat Res Commun. 2019; 18:100114. . View in PubMed
Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):50-60. . View in PubMed
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel J Clin Oncol. 2019 02 10; 37(5):403-410. . View in PubMed
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer World J Urol. 2019 Jan; 37(1):95-105. . View in PubMed
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET Future Oncol. 2018 Mar; 14(6):527-536. . View in PubMed
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis Eur Urol. 2018 11; 74(5):611-620. . View in PubMed
Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727.. View in PubMed
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations Cancer Discov. 2018 07; 8(7):812-821. . View in PubMed
Low-dimensional dynamical characterization of human performance of cancer patients using motion data Clin Biomech (BristolAvon). 2018 07; 56:61-69. . View in PubMed
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer J Clin Oncol. 2018 06 01; 36(16):1579-1587. . View in PubMed
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Ann Oncol. 2018 12 01; 29(12):2371-2378. . View in PubMed
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treat Res Commun. 2018; 16:18-23. . View in PubMed
HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018 02 08; 554(7691):189-194. . View in PubMed
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 J Clin Oncol. 2018 05 20; 36(15):1498-1504. . View in PubMed
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival Clin Cancer Res. 2018 10 01; 24(19):4662-4671. . View in PubMed
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) Clin Cancer Res. 2017 Dec 01; 23(23):7199-7208. . View in PubMed
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer Cancer. 2017 Dec 01; 123(23):4566-4573. . View in PubMed
The evolution of chemotherapy for the treatment of prostate cancer Ann Oncol. 2017 Nov 01; 28(11):2658-2669. . View in PubMed
Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients Clin Genitourin Cancer. 2017 Sep 06. . View in PubMed
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC) Clin Genitourin Cancer. 2017 Jul 14. . View in PubMed
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions Ann Oncol. 2017 Jul 01; 28(7):1484-1494. . View in PubMed
Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. . View in PubMed
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. . View in PubMed
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study Cancer Chemother Pharmacol. 2017 Feb; 79(2):339-351. . View in PubMed
A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Clin Genitourin Cancer. 2017 12; 15(6):742-749. . View in PubMed
Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease J Nucl Med. 2017 12; 58(12):2026-2037. . View in PubMed
Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors J Immigr Minor Health. 2017 12; 19(6):1281-1289. . View in PubMed
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 Clin Genitourin Cancer. 2017 12; 15(6):635-641. . View in PubMed
Robotic salvage retroperitoneal and pelvic lymph node dissection for ‘node-only’ recurrent prostate cancer: technique and initial series BJU Int. 2017 09; 120(3):401-408. . View in PubMed
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) J Patient Rep Outcomes. 2017; 2:27. . View in PubMed
Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet. 2017 01 07; 389(10064):67-76. . View in PubMed
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma N Engl J Med. 2017 03 16; 376(11):1015-1026. . View in PubMed
Isolation of exosomes from whole blood by integrating acoustics and microfluidics Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10584-10589. . View in PubMed
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research Future Oncol. 2016 Dec; 12(23):2689-2699. . View in PubMed
What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. . View in PubMed
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View in PubMed
Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. . View in PubMed
Fabrication of conductive gelatin methacrylate-polyaniline hydrogels Acta Biomater. 2016 Mar; 33:122-30. . View in PubMed
Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile CancerClin Genitourin Cancer. 2016 10; 14(5):450-456. e1. . View in PubMed
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer J Clin Oncol. 2016 05 10; 34(14):1652-9. . View in PubMed
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma J Immunother Cancer. 2016; 4:81. . View in PubMed
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial J Clin Oncol. 2016 05 01; 34(13):1500-9. . View in PubMed
Safety and feasibility of fasting in combination with platinum-based chemotherapy BMC Cancer. 2016 06 10; 16:360. . View in PubMed
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors J Clin Oncol. 2016 07 20; 34(21):2478-83. . View in PubMed
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Onco Targets Ther. 2016; 9:5825-5837. . View in PubMed
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project† Ann Oncol. 2015 Dec; 26(12):2392-8. . View in PubMed
Renal-Cell Cancer–Targeting an Immune Checkpoint or Multiple Kinases N Engl J Med. 2015 Nov 05; 373(19):1872-4. . View in PubMed
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. . View in PubMed
Assessing the damage control resuscitation: development, drivers and direction Emerg Med Australas. 2015 Oct; 27(5):485-7. . View in PubMed
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma Br J Cancer. 2015 Aug 11; 113(4):616-25. . View in PubMed
Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story Urol Oncol. 2015 Aug; 33(8):341-2. . View in PubMed
Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis J Urol. 2015 Aug; 194(2):378-85. . View in PubMed
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. . View in PubMed
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer J Clin Oncol. 2015 May 10; 33(14):1601-8. . View in PubMed
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms Urol Oncol. 2015 May; 33(5):245-60. . View in PubMed
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in PubMed
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study Lancet Oncol. 2015 Apr; 16(4):426-35. . View in PubMed
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Target Oncol. 2015 Mar; 10(1):45-53. . View in PubMed
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases Radiology. 2015 Feb; 274(2):624-5. . View in PubMed
Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review BMC Cancer. 2014 Dec 16; 14:966. . View in PubMed
Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. . View in PubMed
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. . View in PubMed
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. . View in PubMed
Chromoplexy and hypoxic microenvironment drives prostate cancer Lancet Oncol. 2014 Dec; 15(13):1419-1421. . View in PubMed
Oscillometric blood pressure: a review for clinicians J Am Soc Hypertens. 2014 Dec; 8(12):930-8. . View in PubMed
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma Eur J Cancer. 2014 Dec; 50(18):3145-52. . View in PubMed
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma Cancer. 2014 Sep 01; 120(17):2684-93. . View in PubMed
Carboplatin’s fourth decade: still searching for its sweet spot Ann Oncol. 2014 Aug; 25(8):1457-8. . View in PubMed
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States Urol Oncol. 2014 Jul; 32(5):637-44. . View in PubMed
Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression Cell Stem Cell. 2014 Jun 05; 14(6):810-23. . View in PubMed
Skate park injury: a new mechanism of sternoclavicular joint dislocation Emerg Med Australas. 2014 Jun; 26(3):316-7. . View in PubMed
Salvage chemotherapy for refractory germ cell tumors Oncology (Williston Park). 2014 Jun; 28(6):498-500. . View in PubMed
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer J Clin Oncol. 2014 Apr 10; 32(11):1136-42. . View in PubMed
Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. . View in PubMed
Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation Blood Press Monit. 2014 Apr; 19(2):120. . View in PubMed
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 J Natl Cancer Inst. 2014 Apr; 106(4):dju013. . View in PubMed
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study J Immunother Cancer. 2014; 2:2. . View in PubMed
Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases Urology. 2014 Jan; 83(1):159-65. . View in PubMed
Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patientsUrol Oncol. 2014 Jan; 32(1):52. e1-9. . View in PubMed
Novel tyrosine kinase inhibitors for renal cell carcinoma Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. . View in PubMed
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder PLoS One. 2014; 9(8):e105326. . View in PubMed
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. . View in PubMed
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed
Targeted a-particle therapy of bone metastases in prostate cancer Clin Nucl Med. 2013 Dec; 38(12):966-71. . View in PubMed
Differentiating mTOR inhibitors in renal cell carcinoma Cancer Treat Rev. 2013 Nov; 39(7):709-19. . View in PubMed
Neoadjuvant chemotherapy with gemcitabine/cisplatin vsmethotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. . View in PubMed
Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination Allergy. 2013 Sep; 68(9):1136-42. . View in PubMed
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors Invest New Drugs. 2013 Aug; 31(4):1016-22. . View in PubMed
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial Lancet Oncol. 2013 Aug; 14(9):893-900. . View in PubMed
Therapeutic windows and opportunity cost cast upon prostate cancer’s fatal shore Ann Oncol. 2013 Jul; 24(7):1717-1720. . View in PubMed
Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med. 2013 Apr 04; 368(14):1314-25. . View in PubMed
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: ‘plus or minus’ may be a minus Ann Oncol. 2013 Feb; 24(2):270-272. . View in PubMed
Tivozanib in the treatment of renal cell carcinoma Biologics. 2013; 7:139-48. . View in PubMed
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology J Clin Oncol. 2013 Jan 01; 31(1):131-61. . View in PubMed
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings Eur Urol. 2013 Jan; 63(1):58-66. . View in PubMed
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial Lancet Oncol. 2012 Oct; 13(10):1055-62. . View in PubMed
Small cell bladder cancer: biology and management Semin Oncol. 2012 Oct; 39(5):615-8. . View in PubMed
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma J Clin Oncol. 2012 Jul 10; 30(20):2509-15. . View in PubMed
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer Clin Nucl Med. 2012 Jul; 37(7):637-43. . View in PubMed
Immune response to sipuleucel-T in prostate cancer Cancers (Basel). 2012 Apr 18; 4(2):420-41. . View in PubMed
Blood cells and their use in active immunotherapy of prostate cancer Hum Vaccin Immunother. 2012 Apr; 8(4):528-33. . View in PubMed
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer Ann Oncol. 2012 Apr; 23(4):968-73. . View in PubMed
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy BJU Int. 2012 Mar; 109(6):846-54. . View in PubMed
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Mol Cancer Ther. 2012 Mar; 11(3):526-37. . View in PubMed
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol. 2012 Feb 10; 30(5):507-12. . View in PubMed
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer Clin Adv Hematol Oncol. 2011 Dec; 9(12 Suppl 28):1-14; quiz 15-6. . View in PubMed
A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma Int J Clin Oncol. 2011 Oct; 16(5):494-9. . View in PubMed
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer Clin Nucl Med. 2011 Oct; 36(10):961-2. . View in PubMed
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer Maturitas. 2011 Aug; 69(4):296-303. . View in PubMed
Experience with sorafenib and adverse event management Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. . View in PubMed
Show us a sign: the search for “game changing” prostate cancer biomarkers Lancet Oncol. 2011 Mar; 12(3):204-6. . View in PubMed
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer Psychiatr Serv. 2011 Feb; 62(2):162-70. . View in PubMed
Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors Am J Clin Oncol. 2011 Feb; 34(1):27-31. . View in PubMed
Using molecular markers to help predict who will fail after radical prostatectomy Prostate Cancer. 2011; 2011:290160. . View in PubMed
Cabazitaxel in prostate cancer: stretching a string Lancet. 2010 Oct 02; 376(9747):1119-20. . View in PubMed
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial Urology. 2010 Oct; 76(4):923-6. . View in PubMed
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. . View in PubMed
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. . View in PubMed
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys Nat Med. 2010 Mar; 16(3):324-8. . View in PubMed
Fasting and cancer treatment in humans: A case series report Aging (Albany NY). 2009 Dec 31; 1(12):988-1007. . View in PubMed
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 J Clin Oncol. 2009 Dec 01; 27(34):5788-93. . View in PubMed
Perioperative chemotherapy for urothelial cancer: how have we made a “sow’s ear” out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42.. View in PubMed
Targeted therapy in renal cancer Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. . View in PubMed
An evaluation of the completeness of reporting of childhood tuberculosis Eur Respir J. 2009 Jul; 34(1):176-9. . View in PubMed
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs. 2009 Mar; 20(3):179-84. . View in PubMed
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience World J Urol. 2009 Feb; 27(1):39-44. . View in PubMed
COOPERATIVE GROUP TRIALS – SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER Ther Adv Med Oncol. 2009; 1(2):69-77. . View in PubMed
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. . View in PubMed
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin’s lymphoma or multiple myeloma Clin Pharmacokinet. 2009; 48(3):199-209. . View in PubMed
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. . View in PubMed
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer BJU Int. 2008 Dec; 102(11):1601-6. . View in PubMed
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy BJU Int. 2008 Nov; 102(9):1086-91. . View in PubMed
Randomized controlled trial of collaborative care management of depression among low-income patients with cancer J Clin Oncol. 2008 Sep 20; 26(27):4488-96. . View in PubMed
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. . View in PubMed
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro Br J Cancer. 2008 Mar 25; 98(6):1085-93. . View in PubMed
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. . View in PubMed
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. . View in PubMed
Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. . View in PubMed
Pain management, supportive and palliative care in patients with renal cell carcinoma BJU Int. 2007 May; 99(5 Pt B):1305-12. . View in PubMed
Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy J Natl Cancer Inst. 2006 Oct 04; 98(19):1420-4. . View in PubMed
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells Int J Oncol. 2006 Jul; 29(1):225-35. . View in PubMed
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies Cancer. 2006 Jun 15; 106(12):2624-9. . View in PubMed
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J Clin Oncol. 2006 Apr 10; 24(11):1712-9. . View in PubMed
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol. 2006 Apr; 175(4):1245-52. . View in PubMed
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. . View in PubMed
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival Oncogene. 2006 Feb 02; 25(5):769-80. . View in PubMed
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial J Thorac Oncol. 2006 Feb; 1(2):126-34. . View in PubMed
Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis Invest New Drugs. 2006 Jan; 24(1):79-83. . View in PubMed
Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6.. View in PubMed
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases J Urol. 2005 Nov; 174(5):1808-13; discussion 1813. . View in PubMed
Postchemotherapy residual masses in advanced seminoma: current management and outcomes Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. . View in PubMed
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines Mol Cancer Ther. 2005 Jul; 4(7):1105-13. . View in PubMed
Up-regulation of EphB4 in mesothelioma and its biological significance Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. . View in PubMed
EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in PubMed
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy Urol Clin North Am. 2005 May; 32(2):217-30vii. . View in PubMed
Molecular prognostic factors in bladder cancer BJU Int. 2005 Apr; 95(6):739-42. . View in PubMed
Molecular markers of prostate cancer outcome Eur J Cancer. 2005 Apr; 41(6):858-87. . View in PubMed
Angiogenesis-targeted therapies in prostate cancer Clin Prostate Cancer. 2004 Dec; 3(3):165-73. . View in PubMed
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients Cancer. 2004 Jun 15; 100(12):2627-36. . View in PubMed
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6.. View in PubMed
Microscopic and gross extravesical extension in pathological staging of bladder cancer J Urol. 2004 Feb; 171(2 Pt 1):640-5. . View in PubMed
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44.. View in PubMed
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol. 2003 Nov; 170(5):1798-803. . View in PubMed
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. . View in PubMed
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer Oncogene. 2003 Sep 04; 22(38):6005-12. . View in PubMed
Natural history of surgically treated bladder carcinoma with extravesical tumor extension Cancer. 2003 Sep 01; 98(5):955-61. . View in PubMed
A randomized, prospective clinical trial to assess the potential infection risk associated with the PosiFlow needleless connector J Hosp Infect. 2003 Aug; 54(4):288-93. . View in PubMed
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse Cancer Res. 2003 Jul 15; 63(14):4196-203. . View in PubMed
Molecular prognostication in bladder cancer–a current perspective Eur J Cancer. 2003 Jul; 39(11):1501-10. . View in PubMed
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion Cancer. 2003 Apr 15; 97(8):1884-93. . View in PubMed
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3410-5. . View in PubMed
Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression Prostate Cancer Prostatic Dis. 2003; 6(2):174-81. . View in PubMed
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy J Clin Oncol. 2002 Aug 01; 20(15):3206-12. . View in PubMed
Surgery and adjunctive chemotherapy for invasive bladder cancer Surg Oncol. 2002 Jun; 11(1-2):55-63. . View in PubMed
Frequent loss of estrogen receptor-beta expression in prostate cancer Cancer Res. 2001 Jul 15; 61(14):5331-5. . View in PubMed
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med. 2001 Mar 01; 344(9):686; author reply 687-8. . View in PubMed
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients Clin Cancer Res. 2001 Mar; 7(3):544-50. . View in PubMed
Effect of less frequent bathing of preterm infants on skin flora and pathogen colonization J Obstet Gynecol Neonatal Nurs. 2000 Nov-Dec; 29(6):584-9. . View in PubMed
Child Abuse Negl. 2000 May; 24(5):599-610. . View in PubMed
Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy Cancer Res. 2000 Mar 15; 60(6):1585-94. . View in PubMed
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue Clin Cancer Res. 1999 Oct; 5(10):2810-9. . View in PubMed
Stretch-induced mitogen-activated protein kinase activation and interleukin-8 production in type II alveolar cells Chest. 1999 Jul; 116(1 Suppl):89S-90S. . View in PubMed
Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer Cancer Res. 1999 May 15; 59(10):2324-8. . View in PubMed
Analysis of diagnostic metabolites by capillary electrophoresis-mass spectrometry J Chromatogr B Biomed Sci Appl. 1999 Apr 30; 727(1-2):43-52. . View in PubMed
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience Cancer. 1999 Apr 15; 85(8):1758-64. . View in PubMed
Acute renal impairment after immersion and near-drowning J Am Soc Nephrol. 1999 Feb; 10(2):382-6. . View in PubMed
An audit of oestrogen implant hormone replacement therapy Aust N Z J Obstet Gynaecol. 1998 Nov; 38(4):455-60. . View in PubMed
Effect of dimethyl amiloride on chronic hypoxic pulmonary hypertension in rats Chest. 1998 Jul; 114(1 Suppl):69S-70S. . View in PubMed
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40 Cancer Res. 1998 May 01; 58(9):1773-8. . View in PubMed
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users Clin Pharmacokinet. 1997 Nov; 33(5):344-400. . View in PubMed
The changing radiographic presentation of bronchogenic carcinoma with reference to cell types Chest. 1996 Dec; 110(6):1474-9. . View in PubMed
Using patient feedback for creating and improving innovative programs J Healthc Qual. 1996 Jul-Aug; 18(4):26-32. . View in PubMed
Drug interactions of clinical importanceAn updated guide. Drug Saf. 1995 Jun; 12(6):393-452. . View in PubMed
Adverse drug reactions and their measurement in the rheumatic diseases J Rheumatol. 1995 May; 22(5):983-8. . View in PubMed
Radionuclide hepatobiliary scanning in patients with AIDS-related sclerosing cholangitis Clin Nucl Med. 1993 May; 18(5):417-22. . View in PubMed
Persistence of organ- and iso-antigens in vitro in a long-term culture cell line of colonic carcinoma Pathology. 1982 Oct; 14(4):405-8. . View in PubMed

David I Quinn, MD

Overview

Awards

Publications

Similar People